YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD. Financials Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
Equities
002675
CNE100001DP5
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.62 CNY | -1.80% |
|
-1.30% | -25.70% |
| May. 27 | Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug | MT |
| May. 20 | Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,924 | 15,972 | 12,659 | 13,655 | 15,115 | 11,231 | - | - |
| Enterprise Value (EV) 1 | 12,924 | 15,972 | 12,659 | 13,655 | 15,115 | 11,231 | 11,231 | 11,231 |
| P/E ratio | 83.5 x | 38.2 x | 83.5 x | 43.5 x | 72.1 x | 37.6 x | 25.9 x | 25.7 x |
| Yield | - | - | - | 0.91% | 0.68% | 1.1% | 0.81% | 1.76% |
| Capitalization / Revenue | 4.32 x | 4.67 x | 3.24 x | 3.81 x | 4.61 x | 3.35 x | 2.93 x | 2.62 x |
| EV / Revenue | 4.32 x | 4.67 x | 3.24 x | 3.81 x | 4.61 x | 3.35 x | 2.93 x | 2.62 x |
| EV / EBITDA | 26.2 x | 22.3 x | 26.6 x | 23.6 x | 31.1 x | 15.6 x | 11.3 x | 10.2 x |
| EV / FCF | - | - | - | - | -64,615,377 x | - | - | - |
| FCF Yield | - | - | - | - | -0% | - | - | - |
| Price to Book | 3.01 x | 3.57 x | 2.88 x | 2.88 x | 3.17 x | 2.26 x | 2.11 x | 2.06 x |
| Nbr of stocks (in thousands) | 802,214 | 802,214 | 802,214 | 824,596 | 824,596 | 824,596 | - | - |
| Reference price 2 | 16.11 | 19.91 | 15.78 | 16.56 | 18.33 | 13.62 | 13.62 | 13.62 |
| Announcement Date | 2/21/20 | 4/29/21 | 4/28/22 | 4/28/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,993 | 3,419 | 3,912 | 3,583 | 3,276 | 3,357 | 3,834 | 4,279 |
| EBITDA 1 | 492.8 | 715.3 | 476.4 | 578.7 | 485.8 | 720 | 989.6 | 1,104 |
| EBIT 1 | 393.8 | 609.1 | 356.9 | 448.3 | 341.7 | 469.8 | 686.6 | 690.7 |
| Operating Margin | 13.16% | 17.82% | 9.12% | 12.51% | 10.43% | 13.99% | 17.91% | 16.14% |
| Earnings before Tax (EBT) 1 | 395.8 | 611.4 | 356.1 | 445.6 | 337.3 | 467.5 | 684.6 | 688 |
| Net income 1 | 154.7 | 417.8 | 151.6 | 307.3 | 209.7 | 299.7 | 433.7 | 437.5 |
| Net margin | 5.17% | 12.22% | 3.87% | 8.58% | 6.4% | 8.93% | 11.31% | 10.22% |
| EPS 2 | 0.1929 | 0.5208 | 0.1889 | 0.3804 | 0.2543 | 0.3625 | 0.5267 | 0.5300 |
| Free Cash Flow | - | - | - | - | -233.9 | - | - | - |
| FCF margin | - | - | - | - | -7.14% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.1500 | 0.1250 | 0.1500 | 0.1100 | 0.2400 |
| Announcement Date | 2/21/20 | 4/29/21 | 4/28/22 | 4/28/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | -234 | - | - | - |
| ROE (net income / shareholders' equity) | 3.65% | 9.57% | 3.43% | 6.79% | 4.53% | 6.07% | 8.14% | 8.02% |
| ROA (Net income/ Total Assets) | - | - | - | 3.88% | - | 3.75% | 4.9% | 5.1% |
| Assets 1 | - | - | - | 7,917 | - | 7,992 | 8,851 | 8,579 |
| Book Value Per Share 2 | 5.350 | 5.570 | 5.480 | 5.760 | 5.790 | 6.020 | 6.460 | 6.600 |
| Cash Flow per Share 2 | 0.8700 | 0.7100 | 1.180 | 1.210 | 0.3400 | 0.8600 | 0.9400 | 1.000 |
| Capex 1 | 250 | 249 | 530 | 389 | 511 | 375 | 338 | 511 |
| Capex / Sales | 8.36% | 7.27% | 13.54% | 10.86% | 15.6% | 11.16% | 8.82% | 11.94% |
| Announcement Date | 2/21/20 | 4/29/21 | 4/28/22 | 4/28/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.62
CNY
Average target price
17.8
CNY
Spread / Average Target
+30.69%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.70% | 1.58B | |
| +19.08% | 43.46B | |
| +24.43% | 22.61B | |
| +16.48% | 15.15B | |
| +22.78% | 14.83B | |
| +57.41% | 13.08B | |
| -0.05% | 6.79B | |
| -12.44% | 6.72B | |
| -8.87% | 5.73B | |
| +12.71% | 5.45B |
- Stock Market
- Equities
- 002675 Stock
- Financials Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
